An individual’s inherited genetic makeup and acquired genomic variants may account for a significant portion of observable variability in therapy efficacy and toxicity. Pharmacogenomics (PGx) is the concept that treatments can be modified to account for these differences to increase chances of therapeutic efficacy while minimizing risk of adverse effects. This is particularly applicable to oncology in which treatment may be multimodal. Each tumor type has a unique genomic signature that lends to inclusion of targeted therapy but may be associated with cumulative toxicity, such as cardiotoxicity, and can impact quality of life. A greater understanding of therapeutic agents impacted by PGx and subsequent implementation has the potential to improve outcomes and reduce risk of drug-induced adverse effects.

中文翻译：

---

药物基因组学与精准心脏肿瘤学的结合：是否存在协同潜力？


个体遗传的基因组成和获得的基因组变异可能是治疗功效和毒性中可观察到的变异的很大一部分原因。药物基因组学 (PGx) 的概念是，可以修改治疗方法以解释这些差异，以增加治疗效果的机会，同时最大限度地降低不良反应的风险。这尤其适用于治疗可能是多模式的肿瘤学。每种肿瘤类型都有独特的基因组特征，有助于纳入靶向治疗，但可能与累积毒性（例如心脏毒性）相关，并可能影响生活质量。更好地了解受 PGx 影响的治疗药物以及随后的实施有可能改善结果并降低药物引起的不良反应的风险。